Kratom, 7-OH Withdrawal Cases Surge at U.S. Clinics — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Boulder Care saw patients reporting kratom product use climb from 3% of new patients in September 2025 to 14% in August 2026, and nearly a third of new patients starting on buprenorphine in the most recent month reported current kratom or 7-OH use.
- Recovery Centers of America saw its two Massachusetts inpatient clinics jump from roughly 1 kratom patient per week last year to 10–20 per week now, with medical director Myles Jen Kin saying withdrawal is now treated "as if it's fentanyl or oxycodone or heroin."
- The FDA flagged 7-OH products as an emerging opioid threat, and the DEA proposed banning 7-OH above a certain threshold—though the rule isn't yet finalized, numerous states have enacted similar restrictions that clinicians say may be driving people into treatment.
- Federal survey data showed lifetime kratom use rising from roughly 4 million people in 2019 to 5 million in 2023, while poison center exposure reports climbed from 258 to 3,434 over the last decade, with a sharp rise in 2025.
- 7-hydroxymitragynine (7-OH) directly activates the brain's opioid receptors—unlike the dominant alkaloid in raw kratom leaf—and is often misleadingly marketed as a kratom product in gummies and liquid shots sold at gas stations, sometimes contaminated with caffeine, kava, or CBD.
- Clinicians describe two patient profiles: people new to substance use who encounter the products at convenience stores thinking they're benign, and patients in remission from opioid use disorder who try kratom for pain and quickly spiral into high-dose 7-OH dependence.
Why it matters: Patients who lost access to 7-OH after state bans are flooding addiction clinics with withdrawal severe enough to require opioid-use-disorder medications like buprenorphine and methadone—and multiple treatment chains now say the dependence is comparable to fentanyl. That poses a documented relapse risk for people in remission from opioid use disorder, who try kratom products marketed as 'wellness' and quickly spiral into high-dose 7-OH use.
Ask SkimNews
